Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).
Authors
Francesco Raspagliesi (ORCID: https://orcid.org/0000-0001-8953-1657)
Elena Giudice (ORCID: https://orcid.org/0000-0002-8763-6815)
Paolo Scollo (ORCID: https://orcid.org/0000-0001-6275-7488)
Giovanni Scambia (ORCID: https://orcid.org/0000-0002-9503-9041)
Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).
Francesco Raspagliesi, Elena Giudice, Paolo Scollo, Giovanni Scambia et al.
Journal
Journal of Clinical Oncology
Topics
Ovarian cancer diagnosis and treatment
article
Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).
Francesco Raspagliesi, Elena Giudice, Paolo Scollo, Giovanni Scambia, Corrado Terranova, Vanda Salutari, Francesco Plotti, Jada Srinivasa Rao, Roberto Angioli, Sunil Gupta, Violante Di Donato, Maria Grazia Distefano, Caterina Ricci
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(16_suppl)
Institutions
Università Cattolica del Sacro Cuore (IT), Università Campus Bio-Medico (IT), Università degli Studi di Enna Kore (IT), Agostino Gemelli University Polyclinic (IT), Ospedale Cannizzaro (IT), Campus Bio Medico University Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Sapienza University of Rome (IT)